Amneal Pharmaceuticals (AMRX) Free Cash Flow Growth (3y) (2020 - 2026)
Amneal Pharmaceuticals (AMRX) Free Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.01 Bn | 20.85 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.41 Bn | 18.61 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | 39.19% |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.70 Bn | 320.11 Mn | -31.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.40% |
| Dec 31, 2025 | 72.39% |
| Sep 30, 2025 | 12.54% |
| Jun 30, 2025 | 35.12% |
| Mar 31, 2025 | -27.09% |
| Dec 31, 2024 | 31.02% |
| Sep 30, 2024 | 20.29% |
| Jun 30, 2024 | 35.47% |
| Mar 31, 2024 | -28.05% |
| Dec 31, 2023 | 18.12% |
| Sep 30, 2023 | 27.32% |
| Jun 30, 2023 | -28.80% |
| Mar 31, 2023 | 46.14% |
| Dec 31, 2022 | 14.39% |
| Sep 30, 2022 | -16.27% |
| Jun 30, 2022 | -151.00% |
| Mar 31, 2022 | 42.06% |
| Dec 31, 2021 | -42.41% |
| Sep 30, 2021 | 26.22% |
| Jun 30, 2021 | 19.77% |